Business & Finance
Swiss pharmaceutical executive warns proposed generic drug tariffs will hurt patients
American consumers will shoulder the cost of threatened import tariffs, according to CNBC reporting on Sandoz's leadership.
The short version
- Sandoz CEO Richard Saynor warned that American patients will ultimately bear the expenses if proposed import tariffs take effect.[CNBC]
- Donald Trump suggested in July that generic drugs could face 100% duties in 2028, increasing to 200% the following year.[CNBC]
- Generic pharmaceuticals currently represent approximately 90% of all prescriptions dispensed in the United States.[CNBC]
Key facts
- Sandoz CEO Richard Saynor stated that American patients will ultimately carry the burden of proposed import duties on generic drugs.[CNBC]
- Donald Trump stated in July that generic drug imports could see 100% tariffs in 2028 and up to 200% a year later.[CNBC]
- Generic medications constitute roughly 90% of prescriptions filled across the United States.[CNBC]
- Sandoz targets doubling its net sales by 2035 and raising its core profit margin beyond 30%.[CNBC]
What remains uncertain
- Whether the proposed tariffs will be formally enacted or altered before their potential 2028 start date remains unconfirmed.[CNBC]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.